D
프레스티지바이오로직스
334970KOSDAQ의약품 제조업36.0 / 100
Reference Date: 2026-04-13
Financial Score9.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 11.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Prestige BioLogics specializes in contract manufacturing of advanced biopharmaceuticals for domestic and international pharmaceutical companies, offering customized services throughout the development process via its CDEMO business model. In the first half of 2024, antibody drug sales accounted for 68% of total revenue.
Number of Employees
279people
Average Salary
42.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
1.33Industry Average 1.042.5Point
Higher than industry avg (caution)
ROE
-26.56Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
24.16Industry Average 11.980.0Point
2.0x industry avg (risky)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲251.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼26.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.4% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 2,315Won52-week high 4,84052-week low 2,305
1-month return1.0Point
1m -11.30% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral자산재평가결과(자율공시)2026-04-02
- Neutral자산재평가실시결정(자율공시)2026-03-26
- Neutral전환가액의조정2026-03-20